PCV28 COST-EFFECTIVENESS ANALYSIS OF THROMBOPROPHYLACTIC STRATEGIES AFTER HIP FRACTURE REPAIR (HFR)  by Raisch, DW et al.
PCV25
COST-EFFECTIVENESS OF PREHOSPITALVERSUS
INHOSPITALTHROMBOLYSIS FOR ACUTE MYOCARDIAL
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OBJECTIVES: This study aimed to model the cost-effectiveness
of pre-hospital compared with in-hospital thrombolysis for
ST-elevation myocardial infarction (STEMI) from the Brazilian
National Health System perspective. METHODS: A decision-
analytic model was used to model these two strategies. Study
endpoint was life-years gained. Resources use and costs were
estimated from the National Health System perspective. Decision
tree and Markov Model were constructed using the results from
published clinical trials. Costs were applied in Real (R$), 2005
year values. RESULTS: At the time horizon of 20 years, pre-
hospital thrombolysis had an average life expectancy of 11.48
years and in-hospital thrombolysis had an average life expect-
ancy of 11.32 years. Total costs were R$ 5640 for pre-hospital
thrombolysis and R$ 5816 for in-hospital thrombolysis. In-
hospital thrombolysis led an additional cost of R$ 176 per
patient. Pre-hospital thrombolysis led an additional 0.15 years of
life-expectancy gained compared with in-hospital thrombolysis.
CONCLUSION: This model suggests that, from National Health
System perspective, implementing pre-hospital thrombolysis for
ST-elevation myocardial infarction (STEMI) may lead to extra
survival and less cost than in-hospital thrombolysis.
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COST-EFFECTIVENESS OF HIGH DOSE ATORVASTATIN
COMPAREDTO STANDARD DOSE PRAVASTATIN IN
SECONDARY PREVENTION
Borgman B
Pﬁzer, Sollentuna, Sollentuna, Sweden
OBJECTIVES: The purpose of this study was to estimate the
cost-effectiveness comparing high dose Atorvastatin (80 mg) to
standard dose Pravastatin (40 mg) in secondary prevention
setting in Sweden. METHODS: Two-year event rates from
PROVE-IT, where 4162 patients who had been hospitalized for
acute coronary syndrome (ACS) within 10 preceding days were
randomized to either 80 mg Atorvastatin (A80) or 40 mg Prav-
astatin (P40), was used to estimate cost-effectiveness comparing
the lipid lowering therapies. Primary endpoints were death, myo-
cardial infarction, unstable angina, revascularization or stroke.
Costs were given in SEK (2006 price level: 1 EURO = 9.329 SEK)
and measured as unit costs for primary endpoints and drug costs.
RESULTS: Due to fewer events in the A80 arm (622 compared to
739), event costs were considerable lower (40,915,253 SEK)
compared to the P40 arm (47,518,042 SEK). The average total
cost per patient over 2-years was 29,566 SEK in the A80 arm
compared to 24,327 SEK in the P40 arm. The cost per event
avoided by treating patients with A80 compared to P40 was
93540 SEK. The cost per life year gained (LYG) was 51092 SEK.
Given an 80% increase/decrease in the price of P40 cost per LYG
was 39,463/62,744 SEK. Sub-analysis of PROVE-IT at 4 months
after ACS showed that cost per standardized event avoided using
A80 as acute therapy decreased to 20,270 SEK due to signiﬁ-
cantly fewer events in the A80 arm (171 compared to 212) and
minimal difference in total costs (A80/P40 event acute cost was
11,087,967/13,792,349 SEK and average total cost per patient
was 7,336/6,930 SEK). CONCLUSION: Secondary prevention
treatment using intensive lipid lowering therapy with A80 is a
highly cost-effective alternative to treatment with P40 in Sweden.
The cost per event avoided and cost per LYG is well within
acceptable threshold levels.
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OBJECTIVES: Nebivolol was demonstrated to be clinically
effective in patients with chronic heart failure (CHF) in the
SENIORS, the trial mirroring the real life CHF population. The
aim of this analysis is to assess the cost effectiveness of nebivolol
compared with standard treatment in elderly patients with heart
failure. METHODS: An individual patient simulation model,
based on a Markov modeling framework, was developed to
estimate life time costs and quality adjusted life years (QALYs)
for patients starting treatment at the age of 70. The model
consisted of ﬁve health states deﬁned by NYHA class and death.
Patient faced different risks of cardiovascular events or death.
The risk of each event in a given cycle was based on patients’
baseline characteristics and time on treatments. Input data for
the model were populated using individual patient data from the
SENIORS trial. Sensitivity analysis explored the implications of
different starting treatment cohort groups and lengths of treat-
ment beneﬁt. Internal validation compared model and trial based
results for different durations of treatment. RESULTS: In the
base case analysis, the total cost per patient was 4568 and
6287; mean life-years were 7.547 and 8.378; and QALYs were
5.2 and 5.844 over life time for patients aged 70 at starting of
treatment for the standard treatment and nebivolol groups
respectively. The probabilistic sensitivity analysis provided the
incremental cost effectiveness ratio was 2069 (95% CI 1947 to
2217)) per life year, and 2670 (95% CI 2475 to 2918) per
QALY. CONCLUSION: This analysis indicates that nebivolol is
highly cost-effective treatment for elderly patients with heart
failure compared to placebo. Strengths of our analysis included
being based on individual patient simulation, extending the
Markov modeling framework to enable the risk of events to be
varied over time.
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COST-EFFECTIVENESS ANALYSIS OF
THROMBOPROPHYLACTIC STRATEGIES AFTER HIP
FRACTURE REPAIR (HFR)
Raisch DW, Campbell HM,Taylor Z
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OBJECTIVES: Following HFR, deep vein thrombosis (DVT) and
pulmonary embolism (PE) are venous thromboembolic events
(VTE) associated with increased costs. Effectiveness of thrombo-
prophylactic strategies (TS) vary. Our objective was to compare
TS used in HFR for VTE outcomes and cost effectiveness (CE),
from the Veterans Affairs (VA) perspective. Comparative CE of
fondaparinux was assessed, using outcomes from clinical trials
and estimated costs from VA data. METHODS: Using retrospec-
tive, nationwide VA data; TS used among HFR patients (3/1/
2003 to 2/29/2004) were documented. We identiﬁed VTEs using
International Classiﬁcation of Disease, Version 9 codes. VA costs
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for surgery and VTEs were extracted for 49 days post-HFR.
Logistic regressions (LR) with covariates of congestive heart
failure, obesity, cancer, age, and gender were performed
to compare VTE outcomes and mortality by TS, (reference =
enoxaparin). Life-years gained (LYG) from decreased mortality
were estimated from actuarial tables. Sensitivity analyses were
performed on costs and rates of VTE events. RESULTS: Enox-
aparin (n = 750), dalteparin (n = 117), and enoxaparin with
heparin (n = 151) were associated with signiﬁcantly (LR,
P < 0.001) fewer DVTs (1.7%, 2.6%, and 3.3%, respectively)
than enoxaparin plus warfarin (n = 128, 20.1%); with an odds
ratio (OR) and 95% conﬁdence interval (95% CI) equal to 5.1
and 2.9–8.9. PE rate was also signiﬁcantly higher (LR, P = 0.002)
with enoxaparin plus warfarin OR = 6.5, 95% CI = 2.3–18.3.
Dalteparin was least costly and dominated (less costly/more
effective) enoxaparin plus warfarin. Compared to dalteparin,
enoxaparin was associated with an incremental cost-effective
ratio (ICER) of $264,449/DVT avoided and $7,691/LYG.
Fondaparinux was estimated to result in an ICER of $561,645/
DVT avoided and $2,752/LYG. The model was insensitive to
changes in VTE rates, but sensitive to decreases in costs of VTEs
or drugs. CONCLUSION: Dalteparin was most cost-effective,
followed by fondaparinux (based upon clinical trials) and enox-
aparin. Enoxaparin plus warfarin was dominated by other TS.
PCV29
THE COST-EFFECTIVENESS ANALYSIS OF CORONARY
ARTERY DISEASE DIAGNOSTIC PARAMETERS IN A CLINICAL
LABORATORY SETTING
Bogavac-Satnojevic N1, Petrova Ivanova G2, Jelic-Ivanovic Z1,
Memon L3, Spasic S1
1Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia, Serbia
and Montenegro, 2Faculty of Pharmacy, Medical University, Soﬁa, Soﬁa,
Bulgaria, Bulgaria, 3Clinical Chemistry Laboratory, Clinical Centre
“Bežanijska kosa”, Belgrade, Serbia, Serbia and Montenegro
OBJECTIVES: The aim of this study was to analyse the cost-
effectiveness of consecutive supplementing of the Framingham
scoring (FRS) algorithm for coronary artery disease (CAD) risk
assessment with apolipoproteins B and A-I (apoA-I and apoB),
the apo (a) phenotype, lipoprotein (a), and high sensitivity C-
reactive protein (hs-CRP). The perspective of the analysis is the
clinical laboratory setting. METHODS: The study is prospective
diagnosing of 221 CAD patients and 289 controls. First line
testing followed the guidelines for risk assessment based on FRS.
Risk factors included in the FRS are: age, total cholesterol, high
density cholesterol, systolic blood pressure, treatment for hyper-
tension and cigarette smoking. FRS classiﬁes individuals into
those with 10-year risk for CAD of >20% event risk (high risk
group), 10–20% event risk (intermediate risk group) and <10%
event risk (low risk group). The FRS algorithm was supple-
mented with apolipoproteins, lipoproteins and hs-CRP and the
effectiveness was measured in number needed to diagnose
(NND). Total cost of diagnostic procedure was calculated on the
basis of the consumed resources for diagnostic tests, labor time,
and consumables. To evaluate the additional number needed to
be diagnosed for successful CAD risk establishment was per-
formed and incremental cost-effectiveness analysis. RESULTS:
A diagnostic strategy employing FRS followed by apoA-I had
lowest cost per additionally successfully diagnoses patient than
the same strategy followed by hs-CRP in the low (2.63 vs. 24.47
euros) and intermediate risk groups (2.93 vs. 122.86 euros). In
the high-risk group the diagnostic strategy employing apo A-I
was the cost-effective strategy. It had a lower ICER (-9.14 euros)
than the strategy employing hs-CRP (7.16 euros). CONCLU-
SION: Cost-effectiveness analysis of different diagnostic markers
results in improved identiﬁcation of at-risk patients at a lower
health cost for society. In the clinical laboratory setting it is
sufﬁcient to determine apoA-I concentration in addition to FRS
for CAD risk assessment.
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OBJECTIVES: Several clinical trials have shown the added
beneﬁt of clopidogrel in reducing the risk of ischemic events in
patients with non-ST-segment elevation myocardial infarction
(NSTEMI) and unstable angina as well as in ST-segment eleva-
tion myocardial infarction (STEMI). The objective of our study
was to evaluate the cost-effectiveness of clopidogrel in the man-
agement of patients with STEMI in Hungary. METHODS: The
analysis is based on the CLARITY and COMMIT trials, which
have investigated the effect of clopidogrel in patients with
STEMI. A combined decision tree and Markov model was devel-
oped. Effectiveness was measured as the number of life-years
gained (LYG) from clopidogrel treatment. Since existing evidence
indicates similar long-term outcomes after STEMI and NSTEMI,
data from the long-term NSTEMI CURE trial was combined
with one-month data from CLARITY and COMMIT to model
the effect of treatment up to one year. The risk of death, MI and
stroke in an untreated population and long-term survival were
derived from the Swedish Hospital Discharge and Cause of
Death registers. The model was run separately for the two
STEMI trials. A payer perspective was chosen for the analysis.
Costs are reported in Hungarian Forints (HUF) at 2006 price
levels. The annual discount rate was set to 5 percent. RESULTS:
Treatment with clopidogrel for up to one year results in 0,086
LYG at an incremental cost of €40 (HUF 9,820) when using a
patient cohort with the same characteristics and event rates as the
CLARITY population. By comparison, using data from the
COMMIT study, clopidogrel treatment results in 0.134 LYG at
an incremental cost of €572 (HUF 140,662). The incremental
cost-effectiveness ratios thus amount to €464 (HUF114,007)/
LYG and €4,281 (HUF1,052,071)/LYG, respectively. CONCLU-
SION: Treatment of STEMI patients with clopidogrel for up
to one year is cost-effective in Hungary with predicted cost-
effectiveness ratios well below generally accepted thresholds
(€20,000–30,000).
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LONG-TERM COST-EFFECTIVENESS OF RIMONABANT
IN GERMANY
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OBJECTIVES: Obesity is associated with a high risk for diabetes
type-2 (T2DM) and cardiovascular diseases. Rimonabant, the
ﬁrst cannabinoid-1receptor blocker, is a new therapeutic option
for overweight patients with additional risk factors and obese
patients. In the RIO-studies rimonabant showed signiﬁcant
reductions in weight and waist circumference, an improvement
of HbA1c, HDL and triglycerides, when added to diet and exer-
cise. The aim of this study was to evaluate the cost-effectiveness
of rimonabant in patients with BMI 30 kg/m2 or BMI
>27 kg/m2 and additional risk factors from the German SHI-
perspective. METHODS: The previously developed Rainbow
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